New Analysis Clouds Lurasidone’s Japan Schizophrenia Prospects
This article was originally published in PharmAsia News
Executive Summary
The future of Sumitomo Dainippon Pharma's atypical antipsychotic Latuda (lurasidone) in Japan for its main indication of schizophrenia has been thrown into doubt by a deeper analysis of Phase III results.